Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Centocor Inc.

(CNTO)

Lonergan reiterated a "neutral" rating following first quarter sales revenues on

ReoPro

(see BioCentury, Part 1) due to

Read the full 229 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE